IL4 and asthma: Since both IL-4 and IL-13 contribute to a positive feedback loop that promotes TSLP expression, inhibition of their signaling by dupilumab may help mitigate inflammation during virus-induced asthma exacerbations by indirectly reducing TSLP production.